Search

Your search keyword '"Rosa, Kristi"' showing total 23 results
Start Over Author "Rosa, Kristi"
23 results on '"Rosa, Kristi"'

1. Conference Highlights

Author

Dobkowski, Darlene, Rosa, Kristi, and Broderick, Jason M.

Subjects
BCG vaccines -- Conferences, meetings and seminars, Prostate cancer -- Conferences, meetings and seminars -- Care and treatment, BCG -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, Health care industry
Abstract

An analysis of the ARASENS trial (NCT02799602) showed that compared with placebo, darolutamide (Nubeqa) was associated with a numerically lower rate of hospitalization but a longer length of stay when [...]

Published
2024

2. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up

Author

Rosa, Kristi

Subjects
Axitinib -- Analysis, Business, Health care industry
Abstract

Results from a 5-year analysis of the phase 3 KEYNOTE-426 trial (NCT02853331) presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, showed that the [...]

Published
2023

4. How to decide between doublets and triplets in metastatic CSPC

Author

Rosa, Kristi

Subjects
Castration -- Complications and side effects -- Patient outcomes, Prostate cancer -- Care and treatment -- Patient outcomes, Metastasis -- Care and treatment, Business, Health care industry
Abstract

A critical component of the treatment paradigm in metastatic castration-sensitive prostate cancer (mCSPC) is deciding between doublet and triplet regimens, as the treatment standard has moved beyond androgen deprivation therapy [...]

Published
2023

5. 2022 LUGPA ANNUAL MEETING: Chicago, Illinois November 10-12, 2022

Author

Rosa, Kristi and Saylor, Benjamin P.

Subjects
Prostate cancer -- Care and treatment -- Patient outcomes, Continuing medical education -- Conferences, meetings and seminars, Business, Health care industry
Abstract

The 2022 LUGPA Annual Meeting contained a robust continuing medical education (CME) program of clinical content along with updates on health policy and breakout sessions on topics such as staffing [...]

Published
2022

6. UPDATES ON DRUGS, DEVICES, AND TESTS

Author

Broderick, Jason M. and Rosa, Kristi

Subjects
United States. Food and Drug Administration -- Powers and duties, Clinical trials -- Evaluation -- Forecasts and trends, Market trend/market analysis, Business, Health care industry
Abstract

Kidney cancer imaging agent TLX250-CDx succeeds in phase 3 trial The phase 3 ZIRCON trial (NCT03849118) exploring the novel PET imaging radiopharmaceutical TLX250-CDx ([.sup.89]Zr-DFO-girentuximab) in clear cell renal cell carcinoma [...]

Published
2023

7. PostMONARCH Results Show Benefit of Abemaciclib/Fulvestrant.

Author

Rosa, Kristi

Subjects
BREAST tumor prevention, PROTEIN kinase inhibitors, PNEUMONIA, HORMONE receptor positive breast cancer, DRUG side effects, PATIENT safety, BREAST tumors, ANTINEOPLASTIC agents, INFORMATION resources, METASTASIS, FULVESTRANT, DRUG efficacy, PROGRESSION-free survival, TRANSFERASES, SELECTIVE estrogen receptor modulators, BIOMARKERS
Published
2024

8. Liso-Cel Delivers Deep Remissions in R/R CLL/SLL.

Author

Rosa, Kristi

Subjects
CHRONIC lymphocytic leukemia, CELL transplantation, PATIENT safety, DISEASE remission, CELLULAR therapy, CONFERENCES & conventions, TREATMENT effectiveness, DRUG efficacy, PROGRESSION-free survival, CELL receptors
Published
2024

11. GU CANCERS SYMPOSIUM: Conference Highlights. 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY GENITOURINARY CANCERS SYMPOSIUM.

Author

DOBKOWSKI, DARLENE, ROSA, KRISTI, and BRODERICK, JASON M.

Subjects
*THERAPEUTIC use of antineoplastic agents, *ANTIANDROGENS, *COMBINATION drug therapy, *NON-muscle invasive bladder cancer, *HOSPITAL care, *CONFERENCES & conventions, *PROSTATE tumors, *TRANSITIONAL cell carcinoma, BLADDER tumors, GENITOURINARY organ tumors
Abstract

The article discusses highlights of the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium held in San Francisco, California. Topics included link of darolutamide to fewer hospitalizations in metastatic hormone-sensitive prostate cancer patients, cabozantinib and pembrolizumab therapy for urothelial carcinoma, and urinary minimal residual disease-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in non-muscle-invasive bladder cancer.

Published
2024

13. Cilta-Cel Receives Approval for Pretreated R/R Multiple Myeloma.

Author

ROSA, KRISTI

Subjects
MULTIPLE myeloma, IMMUNIZATION, CANCER relapse, DRUG resistance in cancer cells, PATIENT safety, CANCER invasiveness, ANTINEOPLASTIC agents, CELLULAR therapy, DRUG approval, PROTEASE inhibitors, CARBOCYCLIC acids, DRUG efficacy, TUMOR classification, CELL receptors, IMMUNOMODULATORS
Published
2024

14. Linvoseltamab Delivers Deep, Durable Responses in R/R Multiple Myeloma.

Author

Rosa, Kristi

Subjects
THERAPEUTIC use of monoclonal antibodies, MULTIPLE myeloma, RISK assessment, SYNDROMES, PATIENT safety, DRUG side effects, NEUROTOXICOLOGY, DRUG administration, MONOCLONAL antibodies, DRUG efficacy, DISEASE relapse, PROGRESSION-free survival, PATIENT aftercare, OVERALL survival, EVALUATION, DISEASE risk factors
Published
2024

18. Clinical Updates: PROSTATE CANCER. How to decide between doublets and triplets in metastatic CSPC.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *ANTIANDROGENS, *METASTASIS, *ABIRATERONE acetate, *RADIATION, *DOCETAXEL, *PREDNISONE, *PROGRESSION-free survival, *PROSTATE tumors
Abstract

The article reports that androgen deprivation therapy (ADT) intensification for patients with metastatic castration-sensitive prostate cancer (mCSPC) is the standard of care. Topics discussed include triplet regimen with abiraterone, docetaxel and enzalutamide, overall survival benefit with a combination of ADT and an androgen receptor (AR)-targeted agent over ADT alone, and treatment of patients with de novo mCSPC with distant metastatic disease.

Published
2023

19. EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS 2022.

Author

ROSA, KRISTI, SAYLOR, BENJAMIN P., KAHL, KRISTIE L., and BRODERICK, JASON M.

Subjects
*THERAPEUTIC use of monoclonal antibodies, *RENAL cell carcinoma, *CANCER chemotherapy, *PROTEIN kinase inhibitors, *CONFERENCES & conventions, *ABIRATERONE acetate, *ANTINEOPLASTIC agents, *TREATMENT effectiveness, *ONCOLOGY, *ENZYME inhibitors, BLADDER tumors
Abstract

The article highlights studies presented at the European Society for Medical Oncology Congress 2022 in Paris, France from September 9-13, 2022. Topics include finding on the effect of adding olaparib to frontline abiraterone acetate and prednisone/prednisolone, benefits of adding two years of androgen deprivation therapy (ADT) to radiotherapy following radical prostatectomy to men with prostate cancer, and finding on the combination of pembrolizumab and lenvatinib.

Published
2022

21. Uro Pipeline.

Author

Broderick, Jason M. and Rosa, Kristi

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG approval, *MITOMYCINS, *RADIOISOTOPES, *DISEASE relapse, *HEALTH, *INFORMATION resources, *RADIOPHARMACEUTICALS, *POSITRON emission tomography, *NANOMEDICINE, *UROLOGY, *CANCER patient medical care, BLADDER tumors
Abstract

This section offers news briefs pertaining to urology as of January 1, 2023. Topics discussed include clinical trial of a novel positron emission tomography (PET) imaging radiopharmaceutical, enrollment for the Cu-Sarcophagine (SAR)-Bombesin trial, and regulatory updates for mitocyn gel in upper-tract urothelial cancer.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results